Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tozorakimab by AstraZeneca for Asthma: Likelihood of Approval
Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Asthma. According to GlobalData, Phase II drugs...
Tozorakimab by AstraZeneca for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Tozorakimab is under clinical development by AstraZeneca and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Tozorakimab?
Tozorakimab is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Chronic Obstructive Pulmonary Disease (COPD)....